RxDoctor Payments Data

Adegboyega Lawal, MD

Interventional Pain Medicine · Milwaukee, WINPI 1093799504

Payments from drug & device makers

What this record shows

7 manufacturers reported payments, led by Medtronic at 40.4% of the total.

$6,151in general payments, 2019–2025

Across 58 payments — averaging $106.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$1K
  • Stryker$1K
  • Nevro Corp.$603
  • SPR Therapeutics, Inc$260
  • Abbott$166
  • plus $120 from 1 others

What the payments were for

  • Travel & lodging$2,71844%
  • Food & beverage$3,43456%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)30$2,488
Boston Scientific12$1,347
Stryker7$1,167
Nevro Corp.5$603
SPR Therapeutics, Inc2$260
Abbott1$166
Saluda Medical Americas, Inc.1$120

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,151 in reported general payments places this provider in the 65th percentile of 41 interventional pain medicine providers in Wisconsin.

See all interventional pain medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$149,934
Medicare patients
234
Services billed
1,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl19$20,939
Lidocaine62$6,172
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen282$6,082
Gabapentin377$5,955
OxycontinOxycodone Hcl19$5,258
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen216$5,126
Xtampza ErOxycodone Myristate12$4,637
Fentanyl41$4,121
Oxycodone Hcl216$3,392
Pregabalin128$3,177
Tizanidine Hcl197$2,536
Morphine Sulfate ErMorphine Sulfate73$1,965
Cyclobenzaprine Hcl143$1,675
Naloxone Hcl19$1,031
Tramadol Hcl96$867

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →